<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35333125</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1938-2723</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><PubDate><Year>2022</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis</Title><ISOAbbreviation>Clin Appl Thromb Hemost</ISOAbbreviation></Journal><ArticleTitle>Sulodexide: A Benefit for Cardiovascular Sequelae of Long COVID Patients?</ArticleTitle><Pagination><StartPage>10760296221084300</StartPage><MedlinePgn>10760296221084300</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">10760296221084300</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/10760296221084300</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Szolnoky</LastName><ForeName>Gy&#x151;z&#x151;</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-4457-0799</Identifier><AffiliationInfo><Affiliation>Department of Dermatology and Allergology, 37443University of Szeged, Kor&#xe1;nyi fasor 6, H-6720 Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-Ochoa</LastName><ForeName>Alejandro Jos&#xe9;</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Vascular-Endovascular Surgery, CLINEDEM, callej&#xf3;n 5 de mayo y calle 7 No 791, Colonia Comercial, 83449 San Luis Rio Colorado, Sonora, M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Vascular Surgery, Department of Surgery, Hospital General de Zona No12, Instituto Mexicano Seguro Social, San Luis Rio Colorado, Sonora, M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Appl Thromb Hemost</MedlineTA><NlmUniqueID>9508125</NlmUniqueID><ISSNLinking>1076-0296</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006025">Glycosaminoglycans</NameOfSubstance></Chemical><Chemical><RegistryNumber>75HGV0062C</RegistryNumber><NameOfSubstance UI="C007858">glucuronyl glucosamine glycan sulfate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006025" MajorTopicYN="N">Glycosaminoglycans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">anticoagulants</Keyword><Keyword MajorTopicYN="N">endothelial dysfunction</Keyword><Keyword MajorTopicYN="N">sulodexide</Keyword></KeywordList><CoiStatement><b>Declaration of Conflicting Interests:</b> The author(s) declared no potential conflicts of interest with respect to the research,
authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>25</Day><Hour>12</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35333125</ArticleId><ArticleId IdType="pmc">PMC8961374</ArticleId><ArticleId IdType="doi">10.1177/10760296221084300</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Magnani HN. Rationale for the role of heparin and related GAG antithrombotics in COVID-19 infection. Clin Appl Thromb Hemost. 2021;27. doi: 10.1177/1076029620977702</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1076029620977702</ArticleId><ArticleId IdType="pmc">PMC7868468</ArticleId><ArticleId IdType="pubmed">33539214</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez Ochoa AJ, Raffetto J, Hernandez Ibarra AG, et al. Sulodexide in the treatment of patients with early stages of COVID-19: a randomized controlled trial. Thromb Haemostasis. 2021;121(7):944-954. doi: 10.1055/a-1414-5216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1414-5216</ArticleId><ArticleId IdType="pubmed">33677827</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Fogarty H, Dyer A, et al. Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response. J Thromb Haemost. 2021;19(4):1064-1070. doi: 10.1111/jth.15267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15267</ArticleId><ArticleId IdType="pmc">PMC8013297</ArticleId><ArticleId IdType="pubmed">33587810</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H, Townsend L, Morrin H, et al. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J Thromb Haemost. 2021;19(10):2546-2553. doi: 10.1111/jth.15490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15490</ArticleId><ArticleId IdType="pmc">PMC8420256</ArticleId><ArticleId IdType="pubmed">34375505</ArticleId></ArticleIdList></Reference><Reference><Citation>Vollenberg R, Tepasse PR, Ochs K, et al. Indications of persistent glycocalyx damage in convalescent COVID-19 patients: a prospective multicenter study and hypothesis. Viruses. 2021;13(11):2324. doi: 10.3390/v13112324.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13112324</ArticleId><ArticleId IdType="pmc">PMC8619155</ArticleId><ArticleId IdType="pubmed">34835130</ArticleId></ArticleIdList></Reference><Reference><Citation>Pompilio G, Integlia D, Raffetto J, et al. Comparative efficacy and safety of sulodexide and other extended anticoagulation treatments for prevention of recurrent venous thromboembolism: a Bayesian network meta-analysis. TH Open. 2020;4(2):e80-e93. doi: 10.1055/s-0040-1709731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1709731</ArticleId><ArticleId IdType="pmc">PMC7188513</ArticleId><ArticleId IdType="pubmed">32355907</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>